Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

onse to oral glucose tolerance testing as compared to patients receiving placebo (p<0.001 for both dose groups), as measured by area under the curve (AUC).  Consistent with the mechanism of action of LX4211, there was also a significant, dose-dependent increase in 24-hour urinary glucose excretion throughout the study period relative to placebo in both dose groups (p<0.001 at all time points measured).

With respect to broader metabolic and cardiovascular safety parameters, patients in both dose groups showed weight reduction accompanied by decreased blood pressure and triglycerides relative to placebo.  LX4211 demonstrated a favorable safety profile in the study with no dose-limiting toxicities.  Adverse events were generally mild and equally distributed across all groups, including the placebo group.

"The magnitude and rapid response in glycemic control, combined with the triglyceride reduction, may distinguish LX4211 from other agents in this class," said Dr. Brian Zambrowicz, chief scientific officer of Lexicon.  "We now believe that the action of LX4211 cannot be entirely explained by glucose excretion in the urine alone, but may also relate to secondary events that both further enhance glycemic control and provide the other metabolic improvements we have witnessed in this study."

In addition to LX4211, Lexicon has three additional drug candidates progressing through Phase 2 clinical trials: LX1032, a peripherally-available serotonin synthesis inhibitor for carcinoid syndrome; LX2931, an S1P lyase inhibitor for rheumatoid arthritis; and LX1031, a locally-acting serotonin synthesis inhibitor for irritable bowel syndrome, which recently completed a Phase 2a clinical tr
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 San MediTech, the ... continuous glucose monitoring (CGM) for diabetics, announced its plan ... Sessions in Boston on June ... their newest Dynamic Glucose Monitoring System (DGMS). The company ... the world the innovative technologies and advancements made by ...
(Date:6/2/2015)... Mass. , June 2, 2015  PROMETRIKA, ... expanded its offerings with the addition of pharmacovigilance ... a world leader in safety data collection and ... and regulatory affairs professionals, and expert physicians, each ... provide clinical interpretation and monitoring of safety trends. ...
(Date:6/2/2015)... June 2, 2015  Psychemedics Corporation (NASDAQ: PMD ... twenty-five years, announced the addition of 2 new drugs ... growing abuse concerns, the addition of Oxymorphone was made ... added as an option to the Amphetamine panel. ... stated:  "Sadly, more and more prescription drugs are being ...
Breaking Medicine Technology:San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 2San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 3San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 4PROMETRIKA Announces the Availability of Pharmacovigilance Services 2Psychemedics Announces Addition Of FDA Cleared Drugs 2Psychemedics Announces Addition Of FDA Cleared Drugs 3
... on the success of their revolutionary soft cloth nasal ... proud to introduce a mask tube so lightweight and ... Used in the treatment of sleep apnea, ... the CPAP mask with a 15-millimeter hose composed of ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: ... that discovers and develops new uses for previously ... announced that an IRB approved, randomized, vehicle-controlled, double-blinded ... in Denver, Colorado indicates that Ampion™ provides safe ...
Cached Medicine Technology:Circadiance Launches Revolutionary New CPAP Tube 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 3
(Date:6/2/2015)... June 02, 2015 With a dedicated focus ... & Health Care has hired Leslie Young as director ... human resource initiatives to better understand and respond to the ... Tutera’s 47 communities in 13 states across the country. , ... of personalized support to our residents, we are making it ...
(Date:6/2/2015)... June 02, 2015 DiaTech Oncology, ... response profiling test to help oncologists provide personalized ... of American Pathologists (CAP) for its laboratories in ... certification is equivalent to the ‘Good Housekeeping’ seal ... chief executive officer for DiaTech. “It’s a rigorous ...
(Date:6/2/2015)... Though almost the entire Park family was born with HHT, ... lives. Organizing and hosting the June 14 event is just ... fullest and spreading awareness of HHT. , “I've been scanned ... my life in a bubble because something bad might happen,” ... look back on your life with regret because you let ...
(Date:6/2/2015)... 02, 2015 For those that have ... exposed to harmful germs, chemicals and bodily fluids from ... to an inventor from Queens Village, N.Y., their worries ... an efficient, fun, hygienic way to store and dispense ... to bugs, chemicals and germs. Furthermore, it insures that ...
(Date:6/2/2015)... June 02, 2015 The health care ... a pioneering provider of value-based care will now offer ... Orange and Sullivan Counties. The newly launched Crystal Run ... its commercial Small Group Preferred Provider Organization (PPO) and ... Run Healthcare’s Managing Partner and CEO, Hal Teitelbaum, ...
Breaking Medicine News(10 mins):Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 3Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 4Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2Health News:Family brings awareness to genetic disease at first Memphis walk 2Health News:Dental Storage and Dispensing Unit Invented by InventHelp Client (LGI-1890) 2Health News:Leading Health Care Innovator Poised to Deliver New Health Coverage Options To The Hudson Valley Region 2Health News:Leading Health Care Innovator Poised to Deliver New Health Coverage Options To The Hudson Valley Region 3
... , , DURHAM, N.C., Sept. 22 ... chairman and CEO, Chris Stern, will present at an investor conferences in ... will be at the Zurich Airport Radisson Hotel and is scheduled for ... be open to interested investors. , , ...
... , , , FALLS ... (NYSE: CSC ) today announced the successful implementation ... electronic health record (EHR) system, PRISM (Patient Record and Information ... is now operational in the hospital,s inpatient areas as well ...
... , , Changes Reflect Provisions ... Sept. 22 URAC , a leading health care ... now open for proposed changes to its Independent Review Organization (IRO) Standards, ... health plans are encouraged to provide their comments on t he ...
... , , MOUNTAIN VIEW, Calif., ... for clot removal in ischemic stroke patients, today announced the launch ... are a first-in-class family of devices used to provide distal access ... neurovascular procedures. , , The original DAC ...
... , JACKSONVILLE, Fla., Sept. 22 VISTAKON(R), Division of Johnson ... is offering movie fans a chance to win a hometown screening of ... friends. The grand prize also includes autographed skates, poster and book, ... , Fans can enter the ACUVUE(R) WHIP IT Sweeps ...
... , , MOUNTAIN VIEW, Calif., ... today announced publication of results from an in vitro ... development exploring the potential mechanism by which the pharmacokinetics (PK) and ... with intravenous dihydroergotamine (DHE). Results will be published in a manuscript ...
Cached Medicine News:Health News:CSC Helps Fletcher Allen Health Care Implement Phase One of Electronic Health Records System in 15 Months 2Health News:CSC Helps Fletcher Allen Health Care Implement Phase One of Electronic Health Records System in 15 Months 3Health News:URAC Open Public Comment Period for New Independent Review Organization Standards 2Health News:URAC Open Public Comment Period for New Independent Review Organization Standards 3Health News:Concentric Medical Launches Full Family of DAC(TM) Neurovascular Catheters 2Health News:ACUVUE(R) Brand Contact Lenses Gives Movie Fans a Chance to Win a Hometown Screening of WHIP IT 2Health News:ACUVUE(R) Brand Contact Lenses Gives Movie Fans a Chance to Win a Hometown Screening of WHIP IT 3Health News:'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile 2Health News:'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile 3Health News:'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile 4
... a monoclonal antibody based colorimetric test ... Neisseria gonorrhoeae. The test requires less ... no heating or pretreatment. The test ... fresh cultures. GonoGen&trade II eliminates agglutination, ...
Culture Confirmation Tests...
... GC is a novel device for ... Neisseria gonorrhoeae and Neisseria meningitidis. ... life and is easily transportable as ... inoculate, incubate and examine the growth ...
... (Nidek Advanced Vision Information System) is an ... software on a platform designed to communicate ... The network can be expanded in various ... to Nidek products but also to fundus ...
Medicine Products: